Mirvaso (Brimonidine Tartrate)

Brimonidine tartrate, the active ingredient in Mirvaso, is an alpha‑2 adrenergic agonist presented as a 0.33% w/w gel for topical use. It reduces facial erythema associated with rosacea in adult patients by constricting cutaneous blood vessels. It is indicated for the temporary reduction of persistent facial redness and is applied once daily to the affected areas.

GNH USA supplies Mirvaso as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global distribution.

Mirvaso (brimonidine tartrate) is a topical vasoconstrictor used in the management of rosacea‑related facial erythema. - Facial erythema associated with rosacea: reduces visible redness by vasoconstriction. - Persistent facial flushing in rosacea: provides temporary improvement of skin tone. - Adult patients with rosacea‑related redness: offers a once‑daily topical option to manage symptoms.

Common and serious adverse reactions have been reported with topical brimonidine gel.

Common Side Effects: - Application site burning: transient heat sensation. - Stinging or itching: mild irritation. - Dryness of skin: reduced moisture.

Serious or Rare Side Effects: - Allergic contact dermatitis: severe rash with swelling. - Hypotension: systemic blood pressure reduction. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): rare but serious. - Ocular irritation: pain or blurred vision if gel contacts eyes.

When using Mirvaso, consider the following precautions. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; consider potential exposure to infant. - Apply only to intact skin: do not use on broken or inflamed areas. - Avoid ocular contact: keep product away from eyes and mucous membranes. - Concomitant use with other vasoconstrictors: monitor for excessive vasoconstriction. - Store at room temperature: keep in original container, protect from moisture and light.

Potential drug interactions with Mirvaso are outlined below.

Major Interactions (Avoid): - Systemic alpha‑2 agonists (e.g., clonidine): additive hypotensive effect. - MAO inhibitors: possible enhanced cardiovascular effects. - Concurrent use of other topical vasoconstrictors: risk of excessive local vasoconstriction.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may mask irritation signs. - Other rosacea therapies (e.g., ivermectin, azelaic acid): monitor for combined skin effects. - Antihypertensive medications: observe blood pressure if systemic absorption occurs.